Cyclosporine A upregulates platelet-derived growth factor B chain in hyperplastic human gingiva

Salvador Nares, May C. Ng, Russell E. Dill, Bina Park, Christopher W Cutler, Anthony M. Iacopino

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

Cyclosporine A (CSA) is a widely used immunosuppressant for transplant patients and is also used for the treatment of a wide variety of systemic diseases with immunologic components. A prominent side effect of CSA administration is gingival overgrowth (hyperplasia). It has been postulated that CSA alters fibroblast activity through effects on various growth factors/cytokines. However, as yet, data concerning the molecular mechanisms involved in pathologic connective tissue proliferation are preliminary in nature. Our previous investigations concerning phenytoin-induced effects on platelet-derived growth factor B (PDGF-B) gene expression have demonstrated that other drugs which cause gingival overgrowth can upregulate macrophage PDGF-B gene expression in vitro and in vivo. The purpose of the present study was to evaluate PDGF-B gene expression in gingival tissues of patients receiving CSA therapy and exhibiting gingival overgrowth to determine if similar PDGF-B upregulation occurs in response to CSA and to identify PDGF-B producing cells in these tissues. Quantitative competitive reverse transcription polymerase chain reaction (QC-RTPCR) techniques were utilized to measure PDGF-B mRNA levels in CSA overgrowth patients and normal controls (N = 6/group). Results were expressed as mean ± mRNA copy number and tested for significance using unpaired t-tests. Gingival samples were harvested (standardized for local inflammation at the sample site), total RNA was extracted, and QC-RTPCR was performed using specific PDGF-B primers and a corresponding competitive internal standard. CSA-treated patients exhibiting gingival overgrowth demonstrated approximately 48-fold increase in PDGF-B mRNA (7667.1 ± 477.4 copies for CSA patients vs. 158.2 ± 37.1 copies for controls; P < 0.001). Additionally, dual fluorescence immunohistochemistry for mature macrophage marker antigen (CD51) and intracellular PDGF-B was utilized to identify and localize PDGF-B producing cells in hyperplastic gingiva of CSA-treated patients. PDGF-B producing cells were demonstrated to be macrophages distributed in a non-uniform manner throughout the papillary connective tissue. These results further support the hypothesis that the molecular mechanisms responsible for drug-induced gingival overgrowth may involve upregulation of PDGF-B macrophage gene expression. We continue to investigate specific CSA-induced alterations of macrophage PDGF-B gene expression in vitro and in vivo.

Original languageEnglish (US)
Pages (from-to)271-278
Number of pages8
JournalJournal of periodontology
Volume67
Issue number3
DOIs
StatePublished - Jan 1 1996
Externally publishedYes

Fingerprint

Proto-Oncogene Proteins c-sis
Gingiva
Cyclosporine
Up-Regulation
Gingival Overgrowth
Macrophages
Gene Expression
Connective Tissue
Messenger RNA
Reverse Transcription
Gingival Hyperplasia
Polymerase Chain Reaction
Differentiation Antigens
Immune System Diseases
Phenytoin
Immunosuppressive Agents
Pharmaceutical Preparations

Keywords

  • cyclosporine A/adverse effects
  • gene expression
  • gingival hyperplasia/etiology
  • growth factor, platelet-derived
  • macrophages
  • wound healing

ASJC Scopus subject areas

  • Periodontics

Cite this

Cyclosporine A upregulates platelet-derived growth factor B chain in hyperplastic human gingiva. / Nares, Salvador; Ng, May C.; Dill, Russell E.; Park, Bina; Cutler, Christopher W; Iacopino, Anthony M.

In: Journal of periodontology, Vol. 67, No. 3, 01.01.1996, p. 271-278.

Research output: Contribution to journalArticle

Nares, Salvador ; Ng, May C. ; Dill, Russell E. ; Park, Bina ; Cutler, Christopher W ; Iacopino, Anthony M. / Cyclosporine A upregulates platelet-derived growth factor B chain in hyperplastic human gingiva. In: Journal of periodontology. 1996 ; Vol. 67, No. 3. pp. 271-278.
@article{7a297e1606bc4f88a751e1b45cbfc6cb,
title = "Cyclosporine A upregulates platelet-derived growth factor B chain in hyperplastic human gingiva",
abstract = "Cyclosporine A (CSA) is a widely used immunosuppressant for transplant patients and is also used for the treatment of a wide variety of systemic diseases with immunologic components. A prominent side effect of CSA administration is gingival overgrowth (hyperplasia). It has been postulated that CSA alters fibroblast activity through effects on various growth factors/cytokines. However, as yet, data concerning the molecular mechanisms involved in pathologic connective tissue proliferation are preliminary in nature. Our previous investigations concerning phenytoin-induced effects on platelet-derived growth factor B (PDGF-B) gene expression have demonstrated that other drugs which cause gingival overgrowth can upregulate macrophage PDGF-B gene expression in vitro and in vivo. The purpose of the present study was to evaluate PDGF-B gene expression in gingival tissues of patients receiving CSA therapy and exhibiting gingival overgrowth to determine if similar PDGF-B upregulation occurs in response to CSA and to identify PDGF-B producing cells in these tissues. Quantitative competitive reverse transcription polymerase chain reaction (QC-RTPCR) techniques were utilized to measure PDGF-B mRNA levels in CSA overgrowth patients and normal controls (N = 6/group). Results were expressed as mean ± mRNA copy number and tested for significance using unpaired t-tests. Gingival samples were harvested (standardized for local inflammation at the sample site), total RNA was extracted, and QC-RTPCR was performed using specific PDGF-B primers and a corresponding competitive internal standard. CSA-treated patients exhibiting gingival overgrowth demonstrated approximately 48-fold increase in PDGF-B mRNA (7667.1 ± 477.4 copies for CSA patients vs. 158.2 ± 37.1 copies for controls; P < 0.001). Additionally, dual fluorescence immunohistochemistry for mature macrophage marker antigen (CD51) and intracellular PDGF-B was utilized to identify and localize PDGF-B producing cells in hyperplastic gingiva of CSA-treated patients. PDGF-B producing cells were demonstrated to be macrophages distributed in a non-uniform manner throughout the papillary connective tissue. These results further support the hypothesis that the molecular mechanisms responsible for drug-induced gingival overgrowth may involve upregulation of PDGF-B macrophage gene expression. We continue to investigate specific CSA-induced alterations of macrophage PDGF-B gene expression in vitro and in vivo.",
keywords = "cyclosporine A/adverse effects, gene expression, gingival hyperplasia/etiology, growth factor, platelet-derived, macrophages, wound healing",
author = "Salvador Nares and Ng, {May C.} and Dill, {Russell E.} and Bina Park and Cutler, {Christopher W} and Iacopino, {Anthony M.}",
year = "1996",
month = "1",
day = "1",
doi = "10.1902/jop.1996.67.3.271",
language = "English (US)",
volume = "67",
pages = "271--278",
journal = "Journal of Periodontology",
issn = "0022-3492",
publisher = "American Academy of Periodontology",
number = "3",

}

TY - JOUR

T1 - Cyclosporine A upregulates platelet-derived growth factor B chain in hyperplastic human gingiva

AU - Nares, Salvador

AU - Ng, May C.

AU - Dill, Russell E.

AU - Park, Bina

AU - Cutler, Christopher W

AU - Iacopino, Anthony M.

PY - 1996/1/1

Y1 - 1996/1/1

N2 - Cyclosporine A (CSA) is a widely used immunosuppressant for transplant patients and is also used for the treatment of a wide variety of systemic diseases with immunologic components. A prominent side effect of CSA administration is gingival overgrowth (hyperplasia). It has been postulated that CSA alters fibroblast activity through effects on various growth factors/cytokines. However, as yet, data concerning the molecular mechanisms involved in pathologic connective tissue proliferation are preliminary in nature. Our previous investigations concerning phenytoin-induced effects on platelet-derived growth factor B (PDGF-B) gene expression have demonstrated that other drugs which cause gingival overgrowth can upregulate macrophage PDGF-B gene expression in vitro and in vivo. The purpose of the present study was to evaluate PDGF-B gene expression in gingival tissues of patients receiving CSA therapy and exhibiting gingival overgrowth to determine if similar PDGF-B upregulation occurs in response to CSA and to identify PDGF-B producing cells in these tissues. Quantitative competitive reverse transcription polymerase chain reaction (QC-RTPCR) techniques were utilized to measure PDGF-B mRNA levels in CSA overgrowth patients and normal controls (N = 6/group). Results were expressed as mean ± mRNA copy number and tested for significance using unpaired t-tests. Gingival samples were harvested (standardized for local inflammation at the sample site), total RNA was extracted, and QC-RTPCR was performed using specific PDGF-B primers and a corresponding competitive internal standard. CSA-treated patients exhibiting gingival overgrowth demonstrated approximately 48-fold increase in PDGF-B mRNA (7667.1 ± 477.4 copies for CSA patients vs. 158.2 ± 37.1 copies for controls; P < 0.001). Additionally, dual fluorescence immunohistochemistry for mature macrophage marker antigen (CD51) and intracellular PDGF-B was utilized to identify and localize PDGF-B producing cells in hyperplastic gingiva of CSA-treated patients. PDGF-B producing cells were demonstrated to be macrophages distributed in a non-uniform manner throughout the papillary connective tissue. These results further support the hypothesis that the molecular mechanisms responsible for drug-induced gingival overgrowth may involve upregulation of PDGF-B macrophage gene expression. We continue to investigate specific CSA-induced alterations of macrophage PDGF-B gene expression in vitro and in vivo.

AB - Cyclosporine A (CSA) is a widely used immunosuppressant for transplant patients and is also used for the treatment of a wide variety of systemic diseases with immunologic components. A prominent side effect of CSA administration is gingival overgrowth (hyperplasia). It has been postulated that CSA alters fibroblast activity through effects on various growth factors/cytokines. However, as yet, data concerning the molecular mechanisms involved in pathologic connective tissue proliferation are preliminary in nature. Our previous investigations concerning phenytoin-induced effects on platelet-derived growth factor B (PDGF-B) gene expression have demonstrated that other drugs which cause gingival overgrowth can upregulate macrophage PDGF-B gene expression in vitro and in vivo. The purpose of the present study was to evaluate PDGF-B gene expression in gingival tissues of patients receiving CSA therapy and exhibiting gingival overgrowth to determine if similar PDGF-B upregulation occurs in response to CSA and to identify PDGF-B producing cells in these tissues. Quantitative competitive reverse transcription polymerase chain reaction (QC-RTPCR) techniques were utilized to measure PDGF-B mRNA levels in CSA overgrowth patients and normal controls (N = 6/group). Results were expressed as mean ± mRNA copy number and tested for significance using unpaired t-tests. Gingival samples were harvested (standardized for local inflammation at the sample site), total RNA was extracted, and QC-RTPCR was performed using specific PDGF-B primers and a corresponding competitive internal standard. CSA-treated patients exhibiting gingival overgrowth demonstrated approximately 48-fold increase in PDGF-B mRNA (7667.1 ± 477.4 copies for CSA patients vs. 158.2 ± 37.1 copies for controls; P < 0.001). Additionally, dual fluorescence immunohistochemistry for mature macrophage marker antigen (CD51) and intracellular PDGF-B was utilized to identify and localize PDGF-B producing cells in hyperplastic gingiva of CSA-treated patients. PDGF-B producing cells were demonstrated to be macrophages distributed in a non-uniform manner throughout the papillary connective tissue. These results further support the hypothesis that the molecular mechanisms responsible for drug-induced gingival overgrowth may involve upregulation of PDGF-B macrophage gene expression. We continue to investigate specific CSA-induced alterations of macrophage PDGF-B gene expression in vitro and in vivo.

KW - cyclosporine A/adverse effects

KW - gene expression

KW - gingival hyperplasia/etiology

KW - growth factor, platelet-derived

KW - macrophages

KW - wound healing

UR - http://www.scopus.com/inward/record.url?scp=0029964002&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029964002&partnerID=8YFLogxK

U2 - 10.1902/jop.1996.67.3.271

DO - 10.1902/jop.1996.67.3.271

M3 - Article

VL - 67

SP - 271

EP - 278

JO - Journal of Periodontology

JF - Journal of Periodontology

SN - 0022-3492

IS - 3

ER -